Evidence map›Paper›PMID 34883910›Full record

ArticleSensors (Basel, Switzerland)2021

Plasmonic Field-Effect Transistors (TeraFETs) for 6G Communications.

Michael Shur, Gregory Aizin, Taiichi Otsuji, Victor Ryzhii

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael ShurRensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-0976-6232
Gregory AizinKingsborough College, The City University of New York, Brooklyn, NY 11235, USA.
Taiichi OtsujiResearch Institute of Electrical Communication, Tohoku University, Sendai 980-8577, Japan.ORCID 0000-0002-0887-0479
Victor RyzhiiResearch Institute of Electrical Communication, Tohoku University, Sendai 980-8577, Japan.

Funding

Army Research Office No. W911NF-17-S-0002JSPS KAKENHI Nos. 16H06361, 20K20349, and 21H04546U.S. Air Force Office of Scientific Research FA9550-19-1-0355
6 · The paper itself

Abstract

Ever increasing demands of data traffic makes the transition to 6G communications in the 300 GHz band inevitable. Short-channel field-effect transistors (FETs) have demonstrated excellent potential for detection and generation of terahertz (THz) and sub-THz radiation. Such transistors (often referred to as TeraFETs) include short-channel silicon complementary metal oxide (CMOS). The ballistic and quasi-ballistic electron transport in the TeraFET channels determine the TeraFET response at the sub-THz and THz frequencies. TeraFET arrays could form plasmonic crystals with nanoscale unit cells smaller or comparable to the electron mean free path but with the overall dimensions comparable with the radiation wavelength. Such plasmonic crystals have a potential of supporting the transition to 6G communications. The oscillations of the electron density (plasma waves) in the FET channels determine the phase relations between the unit cells of a FET plasmonic crystal. Excited by the impinging radiation and rectified by the device nonlinearities, the plasma waves could detect both the radiation intensity and the phase enabling the line-of-sight terahertz (THz) detection, spectrometry, amplification, and generation for 6G communication.

Indexed as

6G communicationsfield-effect transistor arraysline-of-sight detectionplasma wave instabilitiesplasmonic crystalssilicon CMOSterahertz detectionterahertz generationterahertz radiationtravelling wave amplifier

Identifiers

PMID34883910
PMCPMC8659914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.